2. Signaling Pathways
  3. Protein Tyrosine Kinase/RTK
  4. TAM Receptor
  5. TAM Receptor Isoform
  6. TAM Receptor Inhibitor

TAM Receptor Inhibitor

TAM Receptor Inhibitors (17):

Cat. No. Product Name Effect Purity
  • HY-119039
    RU-301
    		Inhibitor 99.44%
    RU-301 is a pan TAM inhibitor that blocks Gas6-induced TAM activation and tumorigenicity. RU-301 significantly reduces nonalcoholic steatohepatitis (NASH) fibrosis, along with attenuates ERK activation and TGFβ1 expression. RU-301 can be used in studies of cancer and nonalcoholic steatohepatitis.
  • HY-126216
    TAM-IN-2
    		Inhibitor 99.87%
    TAM-IN-2 is a TAM inhibitor extracted from patent US 20170275290 A1, pyrrolotriazine compound 0904.
  • HY-152830A
    Adrixetinib TFA
    		Inhibitor 99.82%
    Adrixetinib (Q702) TFA is a selective Axl/Mer/CSF1R protein tyrosine kinase inhibitor with antineoplastic activity.
  • HY-12432S1
    Gilteritinib-d8
    		Inhibitor ≥98.0%
    Gilteritinib-d8 is deuterium labeled Gilteritinib. Gilteritinib (ASP2215) is a potent and ATP-competitive FLT3/AXL inhibitor with IC50s of 0.29 nM/0.73 nM, respectively.
  • HY-12432R
    Gilteritinib (Standard)
    		Inhibitor
    Gilteritinib (Standard) is the analytical standard of Gilteritinib. This product is intended for research and analytical applications. Gilteritinib (ASP2215) is a potent and ATP-competitive FLT3/AXL inhibitor with IC50s of 0.29 nM/0.73 nM, respectively.
  • HY-120387
    SMU-B
    		Inhibitor
    SMU-B is the orally active inhibitor for ALK (IC50<0.5 nM), c-ros oncogene 1 (ROS1), c-MET (IC50=1.87 nM) and AXL (IC50=28.9 nM). SMU-B inhibits the proliferation of MKN45, H1993 and H441 with IC50s of 0.02 μM, 1.58 μM and 2.82 μM, respectively. SMU-B exhibits antitumor efficacy in mouse models.
  • HY-162940
    MerTK/Axl-IN-1
    		Inhibitor
    MerTK/Axl-IN-1 (Compound A-910) is a potent and selective dual MerTK/Axl inhibitor, with IC50s of 4.2 and 8.8 nM in Ba/F3, and 0.2 and 0.9 nM in HTRF. MerTK/Axl-IN-1 results in pMerTK inhibition in vivo. MerTK/Axl-IN-1 has long half-life, high oral exposure and bioavailability.
  • HY-162645
    BPR5K230
    		Inhibitor
    BPR5K230 is a dual inhibitor for the receptor tyrosine kinase MER and AXL, with IC50 of 4.1 nM and 9.2 nM. BPR5K230 inhibits the proliferation of Ba/F3-MER with IC50 of 5 nM. BPR5K230 exhibits good pharmacokinetic characteristics in mice, exhibits anti-inflammatory and antitumor against 4T1, MDA-MB-231, MC38 and Hepa1?6 in mouse models.
  • HY-152830
    Adrixetinib
    		Inhibitor 99.51%
    Adrixetinib (Q702) is an Axl/Mer/CSF1R protein tyrosine kinase inhibitor with antineoplastic activity.
  • HY-153277
    Axl/Mer/CSF1R-IN-2
    		Inhibitor
    Axl/Mer/CSF1R-IN-2 (Comp 4) is a Axl, Mer and CSF1R inhibitor.
  • HY-162103
    Axl-IN-18
    		Inhibitor
    Axl-IN-18 (compound 25c) is a potent and selective type II AXL inhibitor. Axl-IN-18 shows excellent AXL inhibitory activity (IC50=1.1 nM) and 343-fold selectivity over the highly homologous kinase MET in biochemical assays (IC50=377 nM). Axl-IN-18 significantly inhibits AXL-driven cell proliferation, dose-dependently suppresses 4T1 cell migration and invasion, and induces apoptosis. Axl-IN-18 shows noticeable antitumor efficacy in a BaF3/TEL-AXL xenograft model.
  • HY-169208
    MerTK-IN-1
    		Inhibitor
    MerTK-IN-1 (compund 31) is a MerTK inhibitor with in vivo target binding ability.
  • HY-13016S1
    Cabozantinib-d4
    		Inhibitor
    Cabozantinib-d4 is deuterium labeled Cabozantinib. Cabozantinib is a potent multiple receptor tyrosine kinases (RTKs) inhibitor that inhibits VEGFR2/KDR/Flk-1, c-Met, Kit, Axl and Flt3 with IC50s of 0.035, 1.3, 4.6, 7 and 11.3 nM, respectively.
  • HY-12965B
    (Z)-S49076 hydrochloride
    		Inhibitor
    (Z)-S49076 hydrochloride is an orally active inhibitor of MET and AXL that blocks the downstream signaling of these receptors both in vitro and in vivo, inhibiting the proliferation and migration of tumor cells and suppressing tumor growth in xenograft models. (Z)-S49076 hydrochloride is capable of overcoming the resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) due to MET amplification in Erlotinib (HY-50896)-resistant cell lines both in vitro and in vivo. (Z)-S49076 hydrochloride can be used for research in non-small cell lung cancer (NSCLC).
  • HY-145622
    Mecbotamab vedotin
    		Inhibitor
    Mecbotamab vedotin (BA301) is an IgG1 antibody inhibitor of anti-(human tyrosine kinase receptor AXL) (human-Mus musculus monoclonal BA301 γ1-chain). Mecbotamab vedotin can be used to make immunoconjugates for Methods of Axl-expressing cancers research.
  • HY-13016R
    Cabozantinib (Standard)
    		Inhibitor
    Cabozantinib (Standard) is the analytical standard of Cabozantinib. This product is intended for research and analytical applications. Cabozantinib is a potent and orally active inhibitor of VEGFR2/KDR/Flk-1 and MET, with IC50 values of 0.035, and 1.3 nM, respectively. Cabozantinib displays strong inhibition of KIT, RET, AXL, TIE2, and FLT3 (IC50=4.6, 5.2, 7, 14.3, and 11.3 nM, respectively). Cabozantinib shows antiangiogenic activity. Cabozantinib disrupts tumor vasculature and promotes tumor and endothelial cell apoptosis.
  • HY-164382
    ER-851
    		Inhibitor
    ER-851 is a selective AXL inhibitor with oral activity with IC50 of 100 nM. ER-851 has antitumor activity.